Daewon Pharmaceutical Co., Ltd.

Daewon Pharmaceutical is a leading South Korean pharmaceutical company founded in 1958. It specializes in the development, manufacturing, and distribution of prescription (ETC) and over-the-counter (OTC) drugs, with a particularly strong market position in respiratory treatments, NSAIDs, and cardiovascular medications. The company is known for its 'Incrementally Modified Drugs' (IMDs) and has recently expanded into New Chemical Entities (NCEs) and health functional supplements. In recent years, Daewon has aggressively entered the metabolic disease market, focusing on obesity and diabetes treatments. It operates state-of-the-art cGMP-compliant manufacturing facilities in Hyangnam and a highly automated 'smart factory' in Jincheon, which houses the largest liquid formulation production facility in Korea. The company exports to over 40 countries and is listed on the Korea Stock Exchange (KOSPI).